ROMA指数在上皮性卵巢癌复发中的诊断价值

The diagnostic value of ROMA index in recurrence of epithelial ovarian cancer

目的探讨糖类抗原125(CA125)、人附睾蛋白4(HE4)、卵巢癌风险预测模型(ROMA指数)在上皮性卵巢癌复发中的应用价值。方法收集完成标准初始治疗的上皮性卵巢癌患者81例,根据影像学标准,将患者分为复发组、未复发组,收集患者治疗后CA125、HE4、ROMA指数,绘制受试者工作特征(ROC)曲线并计算曲线下面积(AUC)。结果复发组患者CA125、HE4及ROMA指数在初治后出现变化时间分别为(8.65±4.64)个月、(8.45±3.97)个月、(8.55±4.87)个月,影像学出现变化时间为(10.75±5.04)个月,比较差异有统计学意义(P<0.05)。CA125、HE4与ROMA指数的ROC-AUC分别为0.952、0.900、0.955,CA125、HE4、ROMA指数诊断卵巢癌复发界值分别为35.18 U/mL、109.61 pmol/L、16.34%,灵敏度分别为86.96%、69.57%、91.30%,特异度分别为98.28%、94.83%、91.38%。结论ROMA指数诊断卵巢癌复发的灵敏度优于CA125与HE4。

Objective To evaluate the application value of carbohydrate antigen 125(CA125),human epididymal protein 4(HE4)and ovarian cancer risk prediction model(ROMA index)in epithelial ovarian cancer recurrence.Methods The data of 81 patients with epithelial ovarian cancer who completed standard initial treatment.According to the imaging standard,the patients were divided into the recurrence group and the non-recurrence group,and the CA125,HE4,and ROMA index of patients after treatment were collected.The receiver-operating characteristic(ROC)curve and the area under the curve(AUC)were drawn.Results The changes of CA125,HE4 and ROMA index in the recurrence group after initial treatment were respectively(8.65±4.64)months,(8.45±3.97)months and(8.55±4.87)months.The imaging change was(10.75±5.04)months,and the difference was statistically significant.The ROC-AUC of CA125,HE4 and ROMA index were respectively 0.952,0.900 and 0.955.The diagnostic threshold of CA125,HE4 and ROMA index for recurrence of ovarian cancer were respectively 35.18μ/mL,109.6 pmol/L and 16.34%.The sensitivity was respectively 86.96%,69.57%and 91.30%,and the specificity were respectively 98.28%,94.83%and 91.38%.Conclusion The ROMA index is more sensitive than CA125 and HE4 in diagnosing recurrence of ovarian cancer.